Liquidia (Morrisville, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $13M Series C financing, bringing the total round to $20M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside and Firelake Capital.